COMBINATION THERAPY OF CANCER WITH ANTI-ENDOGLIN ANTIBODIES AND ANTI-PROGRAMMED DEATH RECEPTOR AGENTS

摘要

The present application relates to an anti-endoglin antibody in combination with an anti-PD-1 antibody. The present application relates to an anti-endoglin antibody in combination with an anti-PD-L1 antibody. The present application relates to an anti-endoglin antibody in combination with an anti-PD-1 antibody and an anti-PD-L1 antibody. The present application also relates to an anti-endoglin antibody in combination with Nivolumab, Pidilizumab and PDR001, Pembrolizumab, BMS-936559, Avelumab or Atezolizumab. Another aspect relates to the use of the combinations of the antibodies for use in treating cancers and metastases thereof.